CLINICAL RESEARCH CENTER - ADMN CORE

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 临床研究中心为IRB批准的临床研究提供行政、护理和辅助支持。该中心本身并不进行人类研究。该中心还支持对向公共领域开放的二级数据库的研究。 描述（改编自申请人摘要）：通过RCMI临床研究基础设施倡议，要求对RCMI-CRC提供持续支持。 具体而言，需要继续支持增加护理和饮食工作人员、经过临床培训的流行病学家/生物统计学家以及扩大HAC。 最初资助的德鲁RCMI-CRC申请是朝着扩大该机构以患者护理为导向的研究机会迈出的关键一步。 从历史上看，RCMI-CRC在医学进步中发挥了重要作用，从而为医学实践和医疗保健质量制定了标准。 在德鲁RCMI-CRC的存在导致了临床研究教师和项目的数量增加，致力于调查不成比例地影响少数民族和弱势群体的健康问题。 此外，RCMI-CRC的存在导致了Drewand加州大学洛杉矶分校医学院，Harbor/UCLA，USC，MCW，纽约西奈山医学中心，JHU和杜克。 在RCMI支持的最初四年中，德鲁的以患者护理为导向的研究活动从8个增加到12个;公共卫生服务（PHS）;即美国国立卫生研究院（NIH），疾病控制中心（CDC）资助的临床研究（增加50%）。 最近又资助了另外五个项目，另有三个小灵通申请正在审查中。 这些项目对德鲁来说是一个非凡的机会。 不幸的是，如果没有额外的支持，RCMI-CRC无法处理增加的需求。 为了应对这种机构增长，必须增加资金，以扩大第二区域中心-儿童权利中心的能力。 因此，本次更新申请的主要目标是扩大临床研究活动的广度，并维持越来越多的活跃的临床研究教师。 激素检测核心实验室成立于1996年，由RCMI临床研究中心基础设施计划主持，以扩大查尔斯R。德鲁医学和科学大学，通过开发和提供激素测量方法，当时还没有提供给调查人员。 自三年前成立以来，激素检测实验室不仅实现了所有最初的目标，而且在新的检测开发和检测改进方面超越了它们。在下一个资助期内，核心实验室将实现以下目标：1）继续在德鲁大学提供激素测定能力，不仅进行一些专门的测定，而且还通过提供用于有序地存储和分配来自临床研究的血液样品的设施。2）现有的测定和开发用于测量激素和分析物的新测定将通过适应和开发用于高通量测定的新技术来改进，以用于更常用的激素测量的快速周转。 已经开发了新的测定法a）通过使用高灵敏度平衡透析测定法测量妇女中的游离睾酮，B）肌生长抑制素放射免疫测定法。 在下一个资助期内，我们计划为用户提供以下检测：a）胰岛素，B）C肽，c）IGF-1，d）IGFBP-3，e）C反应蛋白。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The Clinical Research Center provides administrative, nursing, and ancillary support for IRB approved clinical studies. The Center itself does not perform human research. The Center also supports research on secondary databases open to the public domain. DESCRIPTION (Adapted from the applicant''s abstract): Continued support is requested through the RCMI Clinical Research Infrastructure initiative for the RCMI-CRC. Specifically, continued support isrequested for the an increase in the nursing and dietary staffing, aclinically trained epidemiologist/biostatistician and expansion of the HAC. The original funded application for the RCMI-CRC at Drew was the first crucial step toward expanding patient care oriented research opportunities at the institution. Historically, RCMI-CRCs have played an influential role in medical advances, thereby setting standards for the practice of medicine and the quality of health care. The presence of a RCMI-CRC at Drew has led to an increase in the number of clinical research faculty and projects dedicated to the investigation of health issues that disproportionately affect minorities and disadvantaged populations. In addition, the presence of an RCMI-CRC has led to an increase in collaborative clinical research activities between Drewand the UCLA School of Medicine, Harbor/UCLA, USC, MCW, Mount Sinai Medical Center, N.Y., JHU, and Duke. During the initial four years of RCMI support, patient care oriented research activities have increased at Drew from eight to twelve; Public Health Service (PHS); i.e. National Institutes of Health (NIH), Centers for Disease Control(CDC)-funded clinical research studies (50 percent increase). An additional five projects have recently been funded as well as another three PHS applications under review. These projects represent an extraordinary opportunity for Drew. Unfortunately, without additional support, the RCMI-CRC is unable to handle the increased demand. In response to this institutional growth, increased funding is essentia lto expand RCRII- CRC capacity. As such, the broad objective of this renewal application is to expand the breadth of clinical research activities and sustain an increasing number of active clinical research faculty. The Hormone Assay Core Lab was established in 1996 under the auspices of the RCMI Clinical Research Center Infrastructure Initiative to expand the hormone assay capabilities at the Charles R. Drew University of Medicine and Science, by developing and making available hormone measurement methods that were not available to the investigators at that time. Since its inception 3 years ago, the Hormone Assay Laboratory has not only achieved all of its original goals, but has surpassed them in the area of new assay development and assay refinement In the next grant period the Core Laboratory will achieve the following objectives: 1) Continue to provide hormone assay capability at Drew University by not only performing some specialized assays, but by also providing facilities for orderly storage and distribution of blood samples from clinical research studies 2)Existing assays and develop new assays for the measurements of hormones and analytes will be improved by adapting and developing novel technologies for high throughput assays for rapid turnaround formore commonly used hormone measurements. New assays have been developed a) Measurement of Free Testoterone in Women by using a Highly Sensitive Equilibrium Dialysis Assay, b) Myostatin Radioimmunoassay. In the next funding period, we plan to provide the following assays to our users: a) Insulin, b) C-peptide, c)IGF-1,d)IGFBP-3, and e) C reactive protein.